Key regions: United States, Europe, Brazil, Japan, United Kingdom
The Bronchodilator Drugs market in CIS is a growing market due to various factors.
Customer preferences: The demand for bronchodilator drugs in CIS is increasing due to the rising prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). The aging population is also a contributing factor to the growing demand for bronchodilator drugs in the region.
Trends in the market: The trend in the Bronchodilator Drugs market in CIS is towards the increasing use of combination therapies. Combination therapies are becoming more popular due to their effectiveness in treating respiratory diseases. The market is also shifting towards the use of long-acting bronchodilators, which provide sustained relief from symptoms.
Local special circumstances: The Bronchodilator Drugs market in CIS is unique due to the region's healthcare system. The government provides free healthcare to its citizens, which has led to a high demand for affordable medication. This has created an opportunity for local manufacturers to develop and market generic versions of bronchodilator drugs.
Underlying macroeconomic factors: The economic growth in CIS has led to an increase in disposable income, which has resulted in higher healthcare spending. The government has also invested heavily in the healthcare sector, which has led to the development of better healthcare infrastructure. These factors have contributed to the growth of the Bronchodilator Drugs market in CIS.In conclusion, the Bronchodilator Drugs market in CIS is a growing market due to the rising prevalence of respiratory diseases, the trend towards the use of combination therapies and long-acting bronchodilators, the unique healthcare system in the region, and the underlying macroeconomic factors such as economic growth and government investment in healthcare.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
